#22: H/X @ASCO 2012

Healthios Capital Markets, a Chicago-based boutique investment bank focused exclusively on the emerging healthcare community, is proud to announce our exclusive partnering event preceding ASCO this year, entitled “H/X @ ASCO 2012.”

Abbott Laboratories, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celgene, EMD Serono, Forest Laboratories, Genentech, GlaxoSmithKline, Ipsen, Merck, Millennium Pharma, Novartis, Pfizer, Roche, Sanofi, Sunovion and Teva have confirmed so far.

To date, the following companies have confirmed participating: Ambit Biosciences, Ambrx, Acceleron Pharma, Array BioPharma, AVEO, BetaCat Pharmaceuticals, BIND Biosciences, Cerulean Pharma, Cylene Pharma, Dicerna Pharmaceuticals, Eleison Pharmaceuticals, Eleven Biotherapeutics, Fate Therapeutics, Formula Pharmaceuticals, Immunocellular Therapeutics, KaloBios Pharmaceuticals, ParinGenix, Portola Pharmaceuticals, Proacta Therapeutics, Salarius Pharmaceuticals, Theracrine, Tragara Pharmaceuticals, and Verastem.  We are expecting 25-30  emerging growth biotechnology confirmations in the strategically important areas of epigenetics, cancer stem cells (CSCs), immunotherapy, tumor microenvironment, tumor metabolism, anti-angiogenesis, tumor targeting, and next generation cytotoxics.

To kick off our Healthios Partnering meeting at 11:45 a.m. on Friday, June 1, Verastem’s senior management team will keynote our partnering program over lunch by presenting its case study, “Verastem:  Inception to IPO,” chronicling the January 2012 IPO for this cancer stem cell company (http://www.verastem.com). We will be hosting the event at the prestigious Union League Club, 65 W. Jackson, in downtown Chicago.

On Friday, June 1, Strategics will have the opportunity to meet privately for 30 minutes with up to eight emerging growth companies and will have access to the companies’ non-confidential management presentations on our research portal (www.healthios.com/hx).

Pharma/Biotech companies which have participated at previous H/X events include Johnson & Johnson, Sanofi, Novartis, Abbott Labs, Becton Dickinson, Bio-Rad , Gen-Probe, LabCorp, Luminex, Quest Diagnostics, Qiagen, Siemens Healthcare Diagnostics and Sysmex.

Healthios is an investment bank focused exclusively on the emerging growth healthcare community:  strategic buyers, institutional investors and their portfolio companies – with a practice dedicated to Oncology Therapeutics. The Healthios Exchange (“H/X”) is a unique research platform which enables invited users to access the resources, research and relationships which are fundamental to superior value creation. Our partnering events are extensions of the H/X,  as we believe partnering to be at the core of innovative new medicines in Oncology.